Gabapentin Market Size & Share, by Dosage Form (Tablet, Capsule, Oral Solution); Type (Generic, Branded); Application (Neuropathic Pain, Epilepsy, Restless Legs, Syndrome); Distribution Channel (Retail Pharmacy, Hospital Pharmacy, Online Pharmacy) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

  • Report ID: 5130
  • Published Date: Aug 06, 2023
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trends Highlights Over 2023 - 2035

Gabapentin Market size is set to cross USD 6 billion by the end of 2035, growing at a CAGR of 5% during the forecast period 2023 – 2035. In the year 2022, the industry size of gabapentin was 2 billion. The growth of the market can be propelled by the increasing number of people suffering from epilepsy. Since, gabapentin belongs to the family of anticonvulsants it is prescribed to control seizures in individuals with epilepsy. As per a report by World Health Organization, globally 5 million people suffer from epilepsy with an LMC diagnosis rate in epilepsy 139 per 100,000 people. 

Another one of the biggest growth drivers boosting the market expansion is the high utilization of gabapentin as a pain management drug, especially during neuropathic pain. This is largely attributable to an increase in chronic pain for illnesses such as diabetic neuropathy, spinal injuries, and shingles, which are difficult to treat with opioids. In 2021, an estimated 20.9% of U.S. adults experienced chronic pain, and 6.9% of adults experienced high-impact chronic pain. 

Gabapentin Market
Get more information on this report: Request Free Sample PDF

Gabapentin Market: Growth Drivers and Challenges

Growth Drivers

  • Increasing Prevalence of Neuropathic Pain – Gabapentin is largely used to cure neuropathic pain which is caused by damage or dysfunction in the nervous system. The incidence of neuropathic pain all across the globe is growing with various factors such as the growing geriatric population, high prevalence of chronic disease, and increasing awareness of the situation. As per the estimates, the prevalence of neuropathic pain in the general population is around 7% to 10%, expected to grow to around 20% to 30% in people with diabetes in U.K.
  •  Increasing Application in Off-label Indication – Besides treating neuropathic and chronic pain, gabapentin is also used in treating off-label indications such as anxiety disorder, bipolar disorder, insomnia, and others. 
  • Availability of Generic Versions – The generic version of gabapentin has become easily accessible in recent times, and this has made the medication more affordable and attainable for patients.
  •  Supportive Reimbursement Policies – In many countries, healthcare authorities and government initiatives have offered supportive reimbursement policies that have covered gabapentin which makes the medication more affordable and accessible to patients. 
  • Increasing Awareness about Gabapentin – Patients and healthcare professionals are becoming more educated about gabapentin as a viable therapy option as more clinical evidence points to the drug's effectiveness for some conditions.
  • Development of New Formulations – In recent times, new formulations have been developed in the gabapentin domain which enhances efficacy and is easy to use. 


  • Side Effects of Gabapentin – Gabapentin medication gives relief but it also has a few side effects associated with it such as drowsiness, dizziness, and nausea. Besides this, a few serious and harmful side effects are also associated with this medication such as suicidal thoughts, or abnormal behavior. These side effects might pose a limitation on the growth of the market in the upcoming times. 
  • Availability of Alternative Treatments
  • Patent Expiration 

Gabapentin Market: Key Insights

Base Year


Forecast Year

2023 – 2035



Base Year Market Size (2022)

~USD 2 billion

Forecast Year Market Size (2035)

~USD 6 billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Gabapentin Segmentation

Distribution Channel (Retail Pharmacy, Hospital Pharmacy, Online Pharmacy)

The hospital pharmacy segment is anticipated to account for 45% share of the global gabapentin market during the projected period. The hospital pharmacies also have exposure to patients' medical records which leads to high accuracy in medication provision. Besides, the growing demand for advanced healthcare infrastructure, especially in developing countries along with high investment in new technologies and the healthcare sector is expected to influence the segment growth in the upcoming times. Given the risk of misuse, most medicines are provided by hospitals or the healthcare industry. According to a US national survey, 6.6% of persons reported misusing gabapentin at some point in their lives, with therapeutic and non-therapeutic uses split fairly evenly.

Dosage Form (Tablet, Capsule, Oral Solution) 

The capsule segment in the gabapentin market is predicted to witness the largest revenue of 50 % by the end of 2035. The gabapentin medication is available in the market in various forms but the most popular and demanding form is the capsule form, owing to its easy availability, ease of administration, and correct dosing. One of the significant advantages of capsules is that they are easy to swallow which means old people or kids can take them easily and most doctors prescribe capsules over other forms owing to their huge properties. 

Our in-depth analysis of the global gabapentin market includes the following segments:


     Dosage Form

  • Tablet
  • Capsule
  • Oral Solution



  • Generic
  • Branded




  • Neuropathic Pain
  •  Epilepsy
  • Restless Legs
  • Syndrome
  • Others


     Distribution Channel

  • Retail Pharmacy
  • Hospital Pharmacy
  • Online Pharmacy

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Gabapentin Industry- Regional Synopsis

North American Market Statistics

The gabapentin market in the North America region is expected to dominate the global industry, registering the largest market gain of 35% in the estimated period. The growth can be ascribed to the growing prevalence of chronic pain conditions in the region. As the medication is used to treat anxiety, bipolar disorder, nausea, and other off-label indications. It is high in demand in the United States and Canada from this region. As per the data, gabapentin is highly prescribed and is one of the top 30 medications in the United States. 

APAC Market Analysis

The Asia Pacific gabapentin market is poised to account for a significant market value during the forecast timeframe. The growing awareness about the benefits of gabapentin over opioids and increasing healthcare spending in the region is the primary factor boosting the market expansion in the region.  Moreover, various other factors such as the growing geriatric population, rise in government initiatives, research and development by pharmaceutical industries, and increasing product approvals are expected to elevate the growth of the gabapentin market in the region.

Research Nester
Gabapentin Market Size
Get more information on this report: Request Free Sample PDF

Companies Dominating the Gabapentin Market

    • Sun Pharmaceutical Industries Ltd.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Ascend Laboratories
    • LLC Apotex Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Aurobindo Pharma.
    • Amneal Pharmaceuticals LLC.
    • Cipla USA, Inc.
    • BP Pharmaceuticals Laboratories Company
    • Assertio Holdings, Inc.
    • Arbor Pharmaceuticals, Inc.
    • Pfizer Inc.


In The News

· Pfizer Inc. announced the availability of its rheumatoid arthritis biosimilar, RUXIENCE, in July 2021.

· Pfizer Inc. disclosed in September 2021 that it would acquire Amplyx Pharmaceuticals, a privately held business that specializes in creating medications for life-threatening infections.

Author Credits:  Abhishek Verma, Hetal Singh

  • Report ID: 5130
  • Published Date: Aug 06, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The rising prevalence of neuropathic pain and the increasing availability of generic versions are some of the major factors anticipated to drive the growth of the gabapentin market.

The market is anticipated to attain a CAGR of ~5% over the forecast period, i.e., 2023 – 2035.

The major players in the market are Ascend Laboratories, LLC Apotex Inc., Teva Pharmaceutical Industries Ltd., Aurobindo Pharma., Amneal Pharmaceuticals LLC., Cipla USA, Inc., BP Pharmaceuticals Laboratories Company, Assertio Holdings, Inc., Arbor Pharmaceuticals, Inc., and others.

The hospital pharmacy segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.

The market in North America is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.
Gabapentin Market Report Scope

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying